Fundraising FoxPappas Capital — Full Portfolio
82 tracked investments · listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPfizer Venture InvestmentsBiotechnology Value Fund+5 more
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundRA CapitalTCG Crossover+5 more
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Co-investorsAberdare VenturesEcoR1 CapitalInvusPolaris Partners
Liquidia Technologies is a biopharmaceutical company that develops and commercializes drugs for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including YUTREPIA, an inhaled dry-powder treprostinil formulation, and treprostinil injection through a profit-sharing arrangement with Sandoz, along with pipeline candidates based on its PRINT particle-engineering platform.
BiotechMorrisville, US
Kevin Gordon(President and Chief Financial Officer)Robert Lippe(Chief Operations Officer)Benjamin Maynor(Senior Vice President, Research and Development)Timothy Albury(Executive Officer)Neal F. Fowler(Chief Executive Officer)Roger A. Jeffs(Chief Executive Officer)in
Co-investorsCanaan Partners
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalNew Enterprise Associates (NEA)RiverVest Venture PartnersDeerfield Management Company+3 more
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsForesite CapitalSofinnova VenturesvenBio PartnersBlackRockDomain AssociatesMPM BioImpact
Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.
BiotechHealthtech
Co-investorsConnecticut InnovationsSV Health InvestorsDomain Associates
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)inTim Shannon(Director)in
Co-investorsHatteras Venture PartnersOrbiMedCanaan Partners
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Co-investorsDomain AssociatesFidelity InvestmentsJennison AssociatesThird Rock Ventures
BIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations.
BiotechEnterprise SoftwareSheridan, US
Casey Thomas(CEO)
Co-investorsBluepoint PartnersKorea Technology Finance Corporation
Co-investorsHemi Ventures, Llc
BiotechRedwood City, US
Mark Monane(Executive Officer)Gwen R. Carscadden(Executive Officer)David L. Levison(Executive Officer, Director)Deborah L. Kilpatrick(Executive Officer)inRobert F. Werner(Executive Officer)Douglas T. Ross(Executive Officer)
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAlta PartnersAsset Management CompanyCanaan PartnersFrazier Life SciencesSanderling Ventures
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsAlta PartnersLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture Partners+2 more
Emerald BioAgriculture develops biology-based products and solutions using advanced biomanufacturing processes for plant, animal, and human health across various markets.
AgTechBiotechCleantechDeep TechHealthtechNew MaterialsKennett Square, US
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsNew Enterprise Associates (NEA)Canaan Partners
BiotechEast Providence, US
Manny Avila(Executive Officer, Director)inDirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)
BoardDaniel Omstead(Director)Fouad Azzam(Director)inRajeev Dadoo(Director)
Co-investorsLife Sciences PartnersSR One Capital Management
BiotechMorrisville, US
Marc Banjak(Executive Officer)inMatthew W. Farber(Executive Officer)inWilliam G. Nichols(Executive Officer)Matthew R. Stober(Executive Officer, Director)
BoardRobert Bonczek(Director)Raymond Cheong(Director)
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesSolasta VenturesCowen Healthcare InvestmentsEcoR1 CapitalQiming Venture Partners
This is a policy/advocacy page from the National Venture Capital Association (NVCA) about protecting foreign investment into U.S. venture funds and startups, addressing CFIUS regulations.
Washington, US
Bobby Franklin(President and CEO)in
Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
BiotechDigital HealthHealthtechMedical DevicesMontreal, US
Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)
Co-investorsForbionRTW Investments L.P.
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)RiverVest Venture PartnersAbingworthAmzak HealthLundbeckfonden Ventures+2 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesSV Health InvestorsAbbVie+2 more
HealthtechPlymouth, US
Thomas Westling(Executive Officer, Director)inMartha Shadan(Executive Officer, Director)Randy Nuernberg(Executive Officer)Craig Van Kampen(Executive Officer)
BoardFouad Azzam(Director)inScott Weiner(Director)in
Co-investorsNew Enterprise Associates (NEA)LSP (Life Sciences Partners)Pappas Capital
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)inDerek Jantz(Executive Officer)inCharles Gersbach(Director)inJohn McHutchison(CEO, Chairman of the Board)inDan McHugh(Executive Officer, Director)inBlythe Sather(Executive Officer)in
Co-investorsDuke Capital PartnersHatteras Venture PartnersMission BiocapitalNew Enterprise Associates (NEA)Yosemite
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)in
Co-investorsChiesi VenturesSofinnova VenturesVedanta CapitalArix BioscienceOrbiMedPappas Capital+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
10678Aclara BiosciencesAllievexAmplyx PharmaceuticalsAnthera PharmaceuticalsArena PharmaceuticalsArgomedAthersysBalance TherapeuticsBarosenseBayhill TherapeuticsBioAtlaBiosyntechBraincellsCalyx TherapeuticsCenerx BiopharmaCequent PharmaceuticalsCerexaCognetixCoLucid PharmaceuticalsCurzion PharmaceuticalsDynogen PharmaceuticalsEbm SolutionsElitra PhramaceuticalsFlowcardiaGentisLead TherapeuticsLipoScienceLumena PharmaceuticalsMarina BiotechMethylgeneNereusNuvasiveOptherionOrphoMedPanacos PharmaceuticalsPeninsula PharmaceuticalsPlexigenPlexxikonReprogenesisSelventaSensys MedicalSignaseSolu TherapeuticsSphericsSungarddxSyntonix PharmaceuticalsTargegenTesaroThrasos TherapeuticsTyrxUltragenyx PharmaceuticalVariagenicsVeralox TherapeuticsX Ceptor Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.